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ABSTRACT
Heart failure with preserved ejection fraction is a so-
cioeconomic burden in Japan as well as other devel-
oped countries. Diuretics are widely used to attenuate 
symptoms and signs of congestion in both heart failure 
with preserved and reduced ejection fraction, although 
their effects on long-term prognosis of both phenotypes 
of heart failure have not been demonstrated because 
of an ethical difficulty in designing a randomized and 
prospective clinical trial. Guidelines do not provide 
any guidance on therapy choice, and physicians blind-
ly choose furosemide among loop diuretics in current 
clinical settings. However, several clinical studies have 
suggested that the effects of loop diuretics are not con-
sistent, and that furosemide is not necessarily preferable 
as compared with other loop diuretics. We should pay 
attention to the choice of loop diuretics. Regarding the 
improvement of long-term prognosis, angiotensin-con-
verting enzyme inhibitor/angiotensin receptor blocker, 
mineralocorticoid receptor blocker and β-blocker are 
proven effective for heart failure with reduced ejection 
fraction. However, none of these drugs have improved 
prognosis of heart failure with preserved ejection frac-
tion in clinical trials. Observational studies and subanal-
ysis of clinical trials suggest the benefits of these drugs 
in this phenotype of heart failure. All of clinical trials 
and observational studies present facts to us, and let 
us recognize that “one size fits all approach” may be a 
cause for a lack of evidence about the therapeutic strate-
gy of heart failure with preserved ejection fraction until 
now. We have to make efforts to clarify characteristics 
of patients with heart failure and preserved ejection frac-
tion to whom the administration of each drug provides 
benefits or do not.
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About a half of patients with heart failure (HF) have 
normal or near-normal ejection fraction in the current 
era,1, 2 and this phenotype of HF is termed heart failure 
with preserved ejection fraction (HFpEF). The preva-
lence of HFpEF particularly increases with aging (Fig. 1).3 
 The accumulated evidence about the effects of 
therapeutic interventions on HF with reduced ejection 
fraction (HFrEF) has resulted in the improvement of its 
prognosis, although not satisfactorily.4 In contrast, there 
has been no established therapeutic strategy to be effi-
cacious against HFpEF. Its prognosis has not changed 
over the past decades and is currently as poor as that of 
HFrEF.4 Therefore, it is an exigent issue to find out ef-
fective therapeutic intervention for HFpEF.
CHOICE OF DIURETICS FOR HFpEF
Diuretics improve symptoms of HF patients,5 and are 
widely used irrespective of left ventricular ejection frac-
tion. Loop diuretics are most widely used, but little atten-
tion is paid to the difference in their pharmacokinetics. 
Our experimental study showed azosemide, a long-act-
ing loop diuretic, provided better prognosis in HFrEF 
model rats compared with furosemide, a short-acting 
and most widely used diuretic, and this result was partly 
explained by less reflex increase in cardiac sympathetic 
neuronal activity in the azosemide group.6 This finding 
was confirmed by a Japanese clinical trial, J-MELODIC 
study which reported that azosemide, compared with 
furosemide, reduced the risk of cardiovascular death or 
unplanned hospitalization for worsening HF in patients 
with HF.7 This study included both of HFrEF and HF-
pEF, and more than a half of patients were HFpEF. The 
subgroup analysis showed that the results were consis-
tent across left ventricular ejection fraction.
 Torasemide, another long-acting loop diuretic with 
anti-aldosterone effects, is likely to provide beneficial 
effects over furosemide in HF patients.8 There are only 
studies with a small number of patients, and no study 
investigated the effects of torasemide on HFpEF.
 Physicians usually choose furosemide among loop 
diuretics for patients with HF in current clinical settings. 
Guidelines recommend use of diuretics to improve 
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Fig. 1. Difference of cumulative 
incidence of HFpEF and HFrEF 
among cohort studies. With an 
increase in age of study sub-
jects, incidence of HFpEF en-
hances. (Figure was produced 
based on data of reference 3.)
HFpEF, heart failure with pre-
served ejection fraction; HFrEF, 
heart failure with reduced ejec-
tion fraction; PREVEND study, 
Prevention of Renal and Vascu-
lar Endstage Disease study; y.o., 
years old.
symptoms and signs associated with congestion, but do 
not provide any guidance on therapy choice. The previ-
ous our and other studies have strongly suggested that 
the choice of loop diuretics affects clinical outcomes in 
the treatment of HFpEF.
THE EFFECTS OF ANGIOTENSIN CONVERTING 
ENZYME INHIBITOR (ACEI) AND ANGIOTENSIN 
RECEPTOR BLOCKER (ARB) IN HFpEF
Previous clinical trials have demonstrated the beneficial 
effects of ACEI and ARB in HFrEF, and its principal 
mechanism is to prevent structural remodeling such as 
myocardial hypertrophy, fibrosis and ventricular dilata-
tion. Myocardial hypertrophy and fibrosis are also ob-
served in HFpEF patients9, 10 and are considered to play 
crucial roles in the development of signs and symptoms 
of HF. Our experimental studies have shown that the 
administration of ACEI and/or ARB provides beneficial 
effects on HFpEF model rats.11–13  
 Clinical studies have not reached a consensus. Clini-
cal trials to assess the effects of ACEI and ARB on clin-
ical outcomes of HFpEF (Table 1) have failed to reveal 
its benefits.14–16 However, an observational study with a 
larger number of patients demonstrated the prescription 
of ACEI/ARB resulted in the reduction of mortality 
of HFpEF patients.17 There are differences in patients’ 
characteristics between clinical trials and observational 
studies. In addition, the subanalysis of a clinical trial, 
I-Preserve trial, reported the beneficial effects of irbe-
sartan in HFpEF patients with low, but not high, values 
of baseline plasma amino-terminal pro-brain natriuretic 
peptide.18 These experimental and clinical studies sug-
gest that there are a subgroup of HFpEF patients who 
benefit from ACEI or ARB, and we have to abolish “one 
size fits all approach” in searching appropriate treatment 
strategy for HFpEF.
Table 1. Clinical trials to investigate the effects of 
pharmacological intervention on clinical outcomes 
of HFpEF
Trial Drug Primary endpoint
PEP-CHF14 ACEI all cause death or HF hospitaliza-tion
CHARM-Pre-
served16 ARB CV death or HF hospitalization
I-Preserve15 ARB all cause death or CV hospitaliza-tion
TOP-CAT26 MRB CV death, aborted cardiac arrest, or HF hospitalization
J-DHF34 β-blocker CV death and HF hospitalization
DIG ancillary46 Digitalis HF mortality or HF hospitalization
ACEI, angiotensin converting enzyme inhibitor; ARB, angioten-
sin receptor blocker; CV, cardiovascular; HF, heart failure; MRB, 
mineralocorticoid receptor blocker.
THE EFFECTS OF MINERALOCORTICOID RE-
CEPTOR BLOCKER (MRB) IN HFpEF
Previous clinical trials have demonstrated the benefi-
cial effects of MRB in HFrEF. Our experimental study 
showed the administration of MRB was effective in the 
animal model for HFpEF.19 Although a principal ligand 
of the mineralocorticoid receptor is thought to be al-
dosterone, both aldosterone and cortisol/corticosterone 
have the affinity to the mineralocorticoid receptor.20 The 
selective activation of the mineralocorticoid receptor by 
aldosterone is maintained through conversion of active 
cortisol/corticosterone to inactive cortisone/11-dehydro-
corticosterone by 11β-hydroxysteroid dehydrogenase 
type 2 (11β-HSD2) in the tissues; however, 11β-HSD2 is 
minimally detectable in the cardiac tissue.19 Our exper-
imental studies have shown that glucocorticoid induces 
myocyte hypertrophy and enhances collagen production 
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in fibroblasts.21, 22 The glucocorticoid-induced enhance-
ment of collagen production is likely through the inter-
action of elongation factor eleven-nineteen lysine-rich 
leukemia, a co-activator of the mineralocorticoid recep-
tor, with the mineralocorticoid receptor.22 Guder et al. 
reported that higher serum levels of both cortisol and 
aldosterone were independent predictors of increased 
mortality risk in HFrEF patients.23 Therefore, we have 
speculated that both glucocorticoid and mineralocor-
ticoid play important roles in the development of HF, 
partly through the activation of the mineralocorticoid 
receptor-mediated pathway. 
 Several clinical studies have reported that MRB im-
proves left ventricular diastolic function and suppresses 
markers of collagen turnover in HFpEF patients.24, 25 In 
spite of these experimental and clinical studies, the treat-
ment with MRB, spironolactone, did not significantly 
reduce the incidence of the primary composite outcome 
of death from cardiovascular causes, aborted cardiac 
arrest, or hospitalization for heart failure in a large clin-
ical trial, TOPCAT.26 However, hospitalization for heart 
failure was significantly reduced by spironolactone in 
this trial. HFpEF patients are elderly, and their quality 
of life should be underscored besides mortality. It is 
well known that repeated hospitalization result in the 
impairment of functional status of heart failure patients. 
We need to reconsider what is an appropriate endpoint 
for clinical studies to establish therapeutic strategies for 
HFpEF.27
THE EFFECTS OF β-BLOCKER IN HFpEF
It is well known that β-blocker significantly reduces 
mortality and morbidity of HFrEF patients, although 
the mechanisms of its benefits are not well clarified. 
Our clinical study showed that β-blocker improved LV 
diastolic function and symptoms of HFrEF patients even 
without the changes in LV systolic function.28 Our and 
other experimental studies demonstrated that the admin-
istration of β-blocker in the HFpEF model rats improved 
their survival rate.29, 30 In addition, the improvement of 
survival rate was dose-dependent (Fig. 2).30  
 In contrast to HFrEF, there have been only a few 
clinical trials to investigate the effects of β-blocker on 
HFpEF. The subanalysis of SENIORS trial showed 
that the benefits of nebivolol were similar between HF 
patients with EF > and ≤ 35%.31 SWEDIC study com-
pared the changes in several Doppler echocardiographic 
indices derived from the transmitral and pulmonary 
venous flow velocity patterns between HFpEF patients 
treated with and without carvedilol to assess the effects 
of carvedilol on left ventricular diastolic function.32 Al-
though the treatment with carvedilol increased a ratio of 
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Fig. 2. Kaplan-Meier survival curves of the HFpEF model rats of 
an untreated group, a group treated with low dose of bisoprolol (12.5 
mg/kg/day) and a group treated with high dose of bisoprolol (250 
mg/kg/day). The survival rate was improved by the administration 
of bisoprolol, and the effects of bisoprolol were dose-dependent. 
Copyright © 2014 John Wiley and Sons. All rights reserved. (Per-
mission granted from the publisher of reference 30.)
HFpEF, heart failure with preserved ejection fraction.
peak mitral E wave velocity to peak mitral A wave ve-
locity (E/A), the increase in E/A can be induced by both 
improvement and worsening of left ventricular diastolic 
function,33 and it was difficult to make a conclusive re-
mark from these data.
 J-DHF investigated the effects of β-blocker on 
clinical outcomes in HFpEF patients in Japan.34 There 
was no significant difference in the incidence of the 
primary endpoint (cardiovascular death or unplanned 
hospitalization for HF) and another composite endpoint 
(cardiovascular death or unplanned hospitalization for 
any cardiovascular causes) between two groups treated 
with and without carvedilol. However, the subanalysis 
revealed that the prescription of carvedilol at standard 
doses for HF, but not at low doses, was associated with 
the significant reduction of the incidence of cardiovascu-
lar death or unplanned hospitalization for any cardiovas-
cular causes (Fig. 3).  
 Currently, there are no other prospective and ran-
domized trials to investigate the effects of β-blocker on 
HFpEF, and observational studies have reached incon-
sistent results. The meta-analysis of 12 previous studies 
reported that β-blocker provides beneficial effects on 
HFpEF,35 which is consistent with our observational 
study.36 In particular, two studies indicated the dose-de-
pendent benefits of β-blocker as J-DHF study did.37, 
38 Shah et al. demonstrated that benefits of β-blocker 
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for 6 weeks.50 Phosphodiesterase-5 inhibitors are expect-
ed to reduce pulmonary artery pressure and to attenuate 
the severity of HF, however, RELAX trial showed ad-
ministration of sildenafil for 24 weeks did not improve 
exercise capacity or clinical status.51 Both of isosorbide 
mononitrate and sildenafil were expected to provide 
beneficial effects through activation of cyclic guanosine 
monophosphate/protein kinase G (cGMP/PKG) sig-
naling pathway. Although these clinical trials yielded 
disappointing outcomes, they only observed the short-
term effects of each drug and did not assess the effects 
on clinical outcomes. 
 Recent small clinical trials suggested the beneficial 
effects of sacubitril/valsartan (LCZ 696, angiotensin 
receptor neprilysin inhibitor),52 ivabradine,53 or ranola-
zine54 for HFpEF. Some of these new agents are current-
ly under a clinical trial for HFrEF in Japan, and clinical 
trials with larger number of HFpEF patients are ongoing 
in the world.
CONCLUSIONS
Currently, there is no therapeutic intervention proven to 
improve the prognosis of HFpEF by clinical trials, and 
observational studies have demonstrated opposite results 
about the effects of some drugs on HFpEF. The bias of 
the study subjects is always argued against observational 
studies. However, the study subjects of the clinical trial 
do not necessarily represent patients’ characteristics in 
the clinical settings, because many exclusion criteria are 
set. Patients with HFpEF frequently have comorbidities 
and infringe on exclusion criteria. Therefore, the charac-
teristics of HFpEF patients in clinical settings are con-
sistent with those of observational studies rather than the 
clinical trials. HFpEF is a generic term of heterogeneous 
pathophysiology and is not a sole disease. All of clinical 
trials and observational studies present facts to us, and 
let us recognize that “one size fits all approach” may be 
a cause for inconsistent results of previous studies and 
for a lack of evidence about the therapeutic strategy of 
HFpEF until now. We have to make efforts to clarify 
characteristics of patients with HFpEF to whom the ad-
ministration of each drug provides benefits or do not.
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Fig. 3. Kaplan-Meier curves showing the time to first occurrence 
of the prespecified outcome, cardiovascular death or unplanned 
hospitalization for any cardiovascular causes. The carvedilol 
group was further divided into a group treated with carvedilol > 
7.5mg/day (n = 58, standard-dose group) and carvedilol ≤ 7.5mg/
day (n = 62, low-dose group). Control group consists of HFpEF 
patients treated without β-blocker.
Copyright © 2014 John Wiley and Sons. All rights reserved. (Per-
mission granted from the publisher of reference 34.)
CI, confidence interval; HFpEF, heart failure with preserved ejec-
tion fraction; HR, hazard ratio; No., number.
emerged at follow-up for 3 years but not for 1 year in pa-
tients with HFpEF.39 On the other hand, there are studies 
which concluded a lack of beneficial effects of β-blocker 
on HFpEF.40–45 However, all of these studies have at least 
one of the following limitations; the number of the sub-
jects was small, or no attention was paid to the effects of 
the dose or the duration of β-blocker therapy in the data 
analysis.  
OTHER DRUGS AVAILABLE IN JAPAN
DIG ancillary trial reported that digoxin did not reduce 
mortality and all-cause or cardiovascular hospitaliza-
tions of HFpEF patients with sinus rhythm receiving 
ACEI and diuretics.46 The subanalysis of a clinical 
trial, GISSI-HF study, showed a lack of benefits of sta-
tin in HFpEF,47 but, several observational studies have 
reported beneficial effects of statins.48, 49 Nitrates are 
prescribed for symptom relief in HF patients, and this 
may be attributable to the reduction of preload of the 
left ventricle. However, NEAT-HFpEF study showed no 
significant differences in the 6-minute walk distance, 
quality-of-life scores, or N-terminal pro-brain natriuretic 
peptide (NT-proBNP) levels between the HFpEF pa-
tients treated with and without isosorbide mononitrate 
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